Melanotan 1 is a name with both chemical and clinical-development associations. The important distinction is between identifying a peptide and identifying a finished medicine. A shared active-molecule name can guide literature discovery, but does not make a research vial equivalent to the formulation, manufacturing controls or clinical setting used in a medicine’s evidence base.
Connect the names through the chemical substitutions
Cayman Chemical’s own identity sheet lists Melanotan I, afamelanotide and NDP-MSH as names associated with its [Nle4,D-Phe7]-alpha-MSH material. The sheet concerns its acetate product; that salt specification should not be transferred to another supplier’s material.Cayman Chemical — [Nle4,D-Phe7]-alpha-MSH acetate identity sheet (opens in a new tab)
EMA’s afamelanotide assessment prints a 13-residue structure with norleucine at position 4 and D-phenylalanine at position 7, plus N-terminal acetylation and C-terminal amidation. These details distinguish the analogue from native alpha-MSH.EMA — Scenesse public assessment report, active-substance section (opens in a new tab)
| Notation | Identity information |
|---|---|
| Nle4 | Norleucine at the fourth residue |
| D-Phe7 | D-phenylalanine at the seventh residue |
| Ac / terminal NH2 | Acetylated N-terminus / amidated C-terminus |
The Roman numeral I and the number 1 are spelling variants in this context. Melanotan II, however, is a different molecular design, not a stronger concentration of the same 13-residue peptide.
Read the original model work at its experimental scale
Sawyer and colleagues’ 1980 study examined the substituted alpha-MSH analogue in frog-skin and mouse-melanoma assay systems. It reported stronger or more prolonged biological responses than the parent peptide in those settings, alongside resistance to serum-enzyme degradation.Sawyer and colleagues — 4-Norleucine, 7-D-phenylalanine-alpha-MSH (opens in a new tab)
A potency comparison belongs to the assay in which it was measured. It should not become a universal multiplier for every biological response or a prediction about how long a retail material will act in a person.
The early study is useful for understanding why the substitutions attracted research interest. It is not a modern clinical benefit-risk assessment, and the title’s prolonged-activity wording should be read with the actual models in view.
This also separates chemical stability from a finished preparation’s shelf life. Neither the historical assay nor the molecular name establishes storage instructions for another product.
Identify the implant and disease population in clinical research
Langendonk and colleagues’ 2015 report describes two randomised placebo-controlled trials of afamelanotide implants in erythropoietic protoporphyria. The primary efficacy measure concerned direct sunlight exposure without pain, and the report found improvements in that disease-specific setting.Langendonk and colleagues — Afamelanotide for Erythropoietic Protoporphyria (opens in a new tab)
That outcome is not the same as cosmetic tanning in an unrestricted population. It also does not establish prevention of skin cancer or removal of every risk associated with sunlight exposure.
The current EMA page identifies Scenesse as an afamelanotide implant medicine for prevention of phototoxicity in adults with erythropoietic protoporphyria. The regulatory record concerns that medicine and indication.EMA — Scenesse medicine record (opens in a new tab)
State what the supplied research report identifies
Novum’s supplied Melanotan I report describes a synthetic alpha-MSH analogue and reference-standard identity, but does not print the full sequence or identify the reference in enough structural detail to reproduce the comparison independently.Supplied Melanotan I 10 mg report (opens in a new tab)
The report therefore supplies a named material and an analytical reference-match statement. It does not establish equivalence to the afamelanotide implant in the cited trials.
A careful reading note should retain separate entries for the literature structure, the supplied material specification and the clinical formulation. Any unresolved connection belongs in the note rather than being filled with an assumed synonym.
This allows the afamelanotide literature to be discussed accurately while keeping the product’s evidence boundary clear. New research should be added according to its actual molecule, formulation, population and endpoint.
Sources and further detail
- Cayman Chemical — [Nle4,D-Phe7]-alpha-MSH acetate identity sheet (opens in a new tab)
Manufacturer’s own synonym and identity fields read. Used for naming only; its salt, storage, purity and preparation specifications are not transferred to Novum.
- EMA — Scenesse public assessment report, active-substance section (opens in a new tab)
Historical official structural section read for sequence, substitutions and terminal groups. Current indication checked separately on the EMA medicine page.
- Sawyer and colleagues — 4-Norleucine, 7-D-phenylalanine-alpha-MSH (opens in a new tab)
Original 1980 indexed abstract read. Assay-specific observations paraphrased briefly; potency ratios and prolonged activity are not translated into human-use guidance.
- Langendonk and colleagues — Afamelanotide for Erythropoietic Protoporphyria (opens in a new tab)
Original 2015 abstract and NEJM trial-design passage checked. Implant formulation and disease-specific endpoint retained; no administration details reproduced.
- EMA — Scenesse medicine record (opens in a new tab)
Current official product identity and indication checked on 19 September 2026. No UK availability or research-vial authorisation claim made.
- Supplied Melanotan I 10 mg report (opens in a new tab)
Complete supplied report read. Reference-standard identity statement retained without inventing a printed sequence or medicine-equivalence conclusion.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.